|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 31185 |
FusionGeneSummary for RHOB_UBE2D3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: RHOB_UBE2D3 | Fusion gene ID: 31185 | Hgene | Tgene | Gene symbol | RHOB | UBE2D3 | Gene ID | 388 | 7323 |
| Gene name | ras homolog family member B | ubiquitin conjugating enzyme E2 D3 | |
| Synonyms | ARH6|ARHB|MST081|MSTP081|RHOH6 | E2(17)KB3|UBC4/5|UBCH5C | |
| Cytomap | 2p24.1 | 4q24 | |
| Type of gene | protein-coding | protein-coding | |
| Description | rho-related GTP-binding protein RhoBAplysia RAS-related homolog 6h6oncogene RHO H6ras homolog gene family, member Brho cDNA clone 6 | ubiquitin-conjugating enzyme E2 D3(E3-independent) E2 ubiquitin-conjugating enzyme D3E2 ubiquitin-conjugating enzyme D3ubiquitin carrier protein D3ubiquitin conjugating enzyme E2D 3ubiquitin-conjugating enzyme E2(17)KB 3ubiquitin-conjugating enzyme | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P62745 | P61077 | |
| Ensembl transtripts involved in fusion gene | ENST00000272233, | ENST00000453744, ENST00000394801, ENST00000394803, ENST00000394804, ENST00000343106, ENST00000321805, ENST00000350435, ENST00000338145, ENST00000349311, ENST00000504211, ENST00000357194, ENST00000505207, ENST00000507845, ENST00000502404, ENST00000513098, | |
| Fusion gene scores | * DoF score | 5 X 3 X 3=45 | 3 X 3 X 2=18 |
| # samples | 5 | 4 | |
| ** MAII score | log2(5/45*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(4/18*10)=1.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: RHOB [Title/Abstract] AND UBE2D3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | RHOB | GO:0008333 | endosome to lysosome transport | 10508588 |
| Hgene | RHOB | GO:0030336 | negative regulation of cell migration | 20460403 |
| Hgene | RHOB | GO:0070301 | cellular response to hydrogen peroxide | 21373644 |
| Hgene | RHOB | GO:0071479 | cellular response to ionizing radiation | 21373644 |
| Tgene | UBE2D3 | GO:0000209 | protein polyubiquitination | 14765125|16522193 |
| Tgene | UBE2D3 | GO:0006513 | protein monoubiquitination | 20347421 |
| Tgene | UBE2D3 | GO:0016567 | protein ubiquitination | 9990509|21532592 |
| Tgene | UBE2D3 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 20347421 |
| Tgene | UBE2D3 | GO:0051865 | protein autoubiquitination | 21068390 |
| Tgene | UBE2D3 | GO:0070936 | protein K48-linked ubiquitination | 20061386 |
| Tgene | UBE2D3 | GO:0070979 | protein K11-linked ubiquitination | 20061386 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AI126264 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 3UTR-3UTR | ENST00000272233 | ENST00000453744 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000394801 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000394803 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000394804 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000343106 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000321805 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000350435 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000338145 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-3UTR | ENST00000272233 | ENST00000349311 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000504211 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000357194 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000505207 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000507845 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000502404 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
| 3UTR-intron | ENST00000272233 | ENST00000513098 | RHOB | chr2 | 20649036 | - | UBE2D3 | chr4 | 103718434 | + |
Top |
FusionProtFeatures for RHOB_UBE2D3 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| RHOB | UBE2D3 |
| Mediates apoptosis in neoplastically transformed cellsafter DNA damage. Not essential for development but affects celladhesion and growth factor signaling in transformed cells. Plays anegative role in tumorigenesis as deletion causes tumor formation.Involved in intracellular protein trafficking of a number ofproteins. Targets PKN1 to endosomes and is involved in traffickingof the EGF receptor from late endosomes to lysosomes. Alsorequired for stability and nuclear trafficking of AKT1/AKT whichpromotes endothelial cell survival during vascular development.Serves as a microtubule-dependent signal that is required for themyosin contractile ring formation during cell cycle cytokinesis.Required for genotoxic stress-induced cell death in breast cancercells. {ECO:0000269|PubMed:10508588, ECO:0000269|PubMed:15226397,ECO:0000269|PubMed:16236794, ECO:0000269|PubMed:21373644,ECO:0000269|PubMed:9478917}. | Accepts ubiquitin from the E1 complex and catalyzes itscovalent attachment to other proteins. In vitro catalyzes 'Lys-11'-, as well as 'Lys-48'-linked polyubiquitination. Cooperateswith the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for thepolyubiquitination of NFKBIA leading to its subsequent proteasomaldegradation. Acts as an initiator E2, priming the phosphorylatedNFKBIA target at positions 'Lys-21' and/or 'Lys-22' with amonoubiquitin. Ubiquitin chain elongation is then performed byCDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. Acts also as an initiator E2, in conjunctionwith RNF8, for the priming of PCNA. Monoubiquitination of PCNA,and its subsequent polyubiquitination, are essential events in theoperation of the DNA damage tolerance (DDT) pathway that isactivated after DNA damage caused by UV or chemical agents duringS-phase. Associates with the BRCA1/BARD1 E3 ligase complex toperform ubiquitination at DNA damage sites following ionizingradiation leading to DNA repair. Targets DAPK3 for ubiquitinationwhich influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus. In conjunction with the MDM2 andTOPORS E3 ligases, functions ubiquitination of p53/TP53. SupportsNRDP1-mediated ubiquitination and degradation of ERBB3 and ofBRUCE which triggers apoptosis. In conjunction with the CBL E3ligase, targets EGFR for polyubiquitination at the plasma membraneas well as during its internalization and transport on endosomes.In conjunction with the STUB1 E3 quality control E3 ligase,ubiquitinates unfolded proteins to catalyze their immediatedestruction. {ECO:0000269|PubMed:10329681,ECO:0000269|PubMed:11743028, ECO:0000269|PubMed:12646252,ECO:0000269|PubMed:15247280, ECO:0000269|PubMed:15280377,ECO:0000269|PubMed:15496420, ECO:0000269|PubMed:16628214,ECO:0000269|PubMed:18284575, ECO:0000269|PubMed:18508924,ECO:0000269|PubMed:18515077, ECO:0000269|PubMed:18948756,ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:20347421,ECO:0000269|PubMed:21532592}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for RHOB_UBE2D3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for RHOB_UBE2D3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for RHOB_UBE2D3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | RHOB | P62745 | DB00083 | Botulinum Toxin Type A | Rho-related GTP-binding protein RhoB | biotech | approved|investigational |
Top |
RelatedDiseases for RHOB_UBE2D3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | RHOB | C0036421 | Systemic Scleroderma | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|